Moleculin Announces Publication Of 90-Patient Pooled Analysis Showing No Heart Toxicity With Annamycin, Including Above Standard Dose Limits
Share
Why It Matters
Moleculin tested a cancer drug on 90 patients and found it did not hurt hearts. When a medicine looks safe in real patients, people pay attention to whether the company might move forward.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.